InflammaSacra
Horizontal, symptom- and phase-oriented support line for pain, irritation and inflammatory tissue reactivity — applicable anywhere on the body.
InflammaSacra is not part of the vertical metameric coverage. It is a horizontal, symptom- and time-bound support line, documented in three stages that follow the clinical phase rather than a segment or dermatome.
Label QR
Opens the public information page in the reader's language.
https://www.siriamlab.com/qr/inflammasacra
Open patient pageEssential reading. The complete scientific monograph is one click away.
Chapter 01
Product identity
Identification, classification, family, intended use, anatomical region and the documents this record is governed by.
Identification of the record: product identifier, classification, family, intended use, anatomical region and the controlled documents it is governed by.
Documentation metadata+
Chapter 01 — related anatomy
Related documents
Future references
- GTIN / label identifierReservedCommercial identifier reserved for the published label.
Record identification
- Product ID
- SIR-INF-01
- Family
- INFLAMMASACRA
- Region
- Systemic — specialist record
- Last update
- 2025-08
Handbook source
Neurodermal regulation of muscular, tendinous, fascial and peripheral nerve irritation across three clinical stages.
- Phase I: acute neurodermal release (0–6 weeks)
- Phase II: transitus — subacute vegetative transition (6 weeks – 3 months)
- Phase III: integralis — chronic integration and stabilisation (>3 months)
- Developer
- MT DO, DCP
- Pharmacist
- AVA
- Chapter version
- 2.0
- Product ID
- SIR-INF-01
The handbook is the scientific master. Every statement rendered on this record originates from this chapter; the platform never creates independent scientific content.
Chapter 02
Executive summary
The record in short: professional summary, patient summary and the sequential treatment model behind it.
The record read in short: professional summary, patient summary and the sequential treatment model behind the formulation.
Documentation metadata+
Chapter 02 — related anatomy
Declared; content in preparation.
Related documents
Future references
- TranslationsReservedExecutive summary in Dutch, French and German.
Executive summary
The reading entry of the record: what the composition is for, in professional and in patient language.
Purpose
Documents a phase-oriented routine — acute, transitional and chronic — that may accompany a regional formulation when clinically indicated, while keeping an independent formulation philosophy.
Clinical goal
Primary anatomical region
sacrum
Primary therapeutic objective
Documented cutaneous topical composition maintained as a specialist record within the ecosystem.
Professional summary
InflammaSacra constitutes the symptom- and phase-oriented support platform of the SIRIAM ecosystem. It sits on a different design axis than the regional DUO system: a patient may, for example, use TLO DUO for the underlying metameric recovery restriction and InflammaSacra I locally on a symptomatic tendon or pain zone. These are not competing records.
Patient summary
Horizontal, symptom- and phase-oriented support line for pain, irritation and inflammatory tissue reactivity — applicable anywhere on the body.
Keywords
Chapter 03
Anatomy snapshot
The anatomical region of the record and every structure of its application field, resolving into the Neuro Atlas.
The anatomical identity of the record: the region, the segmental levels and the surface territory the formulation is documented for.
Documentation metadata+
Chapter 03 — related anatomy
Related documents
Future references
- 3D Atlas referenceReservedVolumetric reference of the field, prepared for the atlas engine.
- EMG referenceReservedFunctional EMG dataset linked to the segmental levels of this record.
- SRST referenceReservedSegmental reflex surface topography mapping.
Snapshot
Anatomy snapshot
Six metameric expressions per segment — dermatome, myotome, sclerotome, viscerotome, micro-angiotome and neurotome. Individual structures inside an expression open their own illustration plate.
Anatomical identity
Primary region
Dermatomes
Declared; content in preparation.
Peripheral nerves
Declared; content in preparation.
Plexus
Declared; content in preparation.
Metamers
Declared; content in preparation.
Neurocutaneous territories
Declared; content in preparation.
Body regions
Surface anatomy
- 3D Atlas referenceReservedVolumetric field reference.
- EMG referenceReservedFunctional EMG dataset.
- SRST referenceReservedSegmental reflex surface topography.
Chapter 04
Clinical purpose
Objective, strategy, workflow and the boundaries within which this record is documented.
The clinical objective of the record, its rationale, and the boundaries within which it is documented.
Documentation metadata+
Chapter 04 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Evidence levelReservedGraded evidence classification per documented statement.
- Clinical casesReservedStructured practitioner observations linked to this record.
Purpose
Why this formulation exists
InflammaSacra constitutes the symptom- and phase-oriented support platform of the SIRIAM ecosystem. It sits on a different design axis than the regional DUO system: a patient may, for example, use TLO DUO for the underlying metameric recovery restriction and InflammaSacra I locally on a symptomatic tendon or pain zone. These are not competing records.
Why this record exists
Documents a phase-oriented routine — acute, transitional and chronic — that may accompany a regional formulation when clinically indicated, while keeping an independent formulation philosophy.
Neurocutaneous region it was designed for
Sacrum surface field, defined by its segmental range.
Anatomical interface it addresses
Sacral surface projection across the posterior pelvic base and perineal field.
Clinical philosophy
Because the line follows the clinical phase rather than a segmental level, the application field is a local tissue zone: muscular, tendinous, fascial, ligamentary or peripheral nerve. Stage I is evaluated after approximately six weeks; stage II shifts toward recovery, microcirculation, vegetative regulation and integration; stage III lowers PEA and Boswellia further and moves deliberately toward stability and chronic integration.
- Cutaneous topical composition; the application field is defined by the treating professional.
- Application is documented per session so routines remain comparable over time.
Chapter 05
Application protocol
Timeline, application sites, professional and patient instructions, safety and storage.
Phases, cadence, duration, zone order and the documented application sequence, with practitioner and patient notes.
Documentation metadata+
Chapter 05 — related anatomy
Related documents
Future references
- Printable protocolReservedPrint-ready protocol sheet generated from this record.
Surface
Application zones
The zones listed are possible application locations. The practitioner identifies the exact spot within these possibilities using the SRST (Segmental Reflex Sensitisation Test). Future evaluation will use EMG before and after application.
Local muscular zone
Detailed application guidance is in preparation.
Application fieldTendon and insertion zone
Detailed application guidance is in preparation.
Application fieldFascial plane
Detailed application guidance is in preparation.
Application fieldLigamentary zone
Detailed application guidance is in preparation.
Application fieldPeripheral nerve zone
Detailed application guidance is in preparation.
Application field
Protocol
Application protocol
Phase I — Neurodermal Release
Acute / first six weeks
1–2 applications per day
Acute phase, first ~6 weeks
Local support for pain, irritation and inflammatory tissue reactivity across muscular, tendinous, fascial, ligamentary and peripheral nerve zones. Evaluated after approximately six weeks.
Phase II — Transitus
Six weeks to three months
1–2 applications per day
Week 6 to month 3
The routine shifts from inflammatory activity toward recovery and regulation: microcirculation, vegetative regulation and tissue integration.
Phase III — Integralis
Beyond three months
1 application per day, reviewed periodically
From month 3, ongoing
PEA and Boswellia are lowered further and the composition moves deliberately toward chronic stabilisation and tissue integration.
Zone sequence
- 01Local muscular zone
- 02Tendon and insertion zone
- 03Fascial plane
- 04Ligamentary zone
- 05Peripheral nerve zone
- 01Apply to the local symptomatic tissue zone identified by the professional.
- 02Stay within one stage until the agreed evaluation moment.
- 03Record the zone, the stage and the date at every session.
Application field on the atlas figure. Levels resolve into the Neuro Atlas.
Zone
The local tissue zone is identified and documented — not a segment or dermatome.
Stage
Stage I, II or III is chosen by clinical phase, not by region.
Evaluation
Stage I is reviewed at ~6 weeks; transitions to II and III follow that review.
InflammaSacra protocol (definitive, three stages)
Zones
- Muscular and tendinous zones
- Fascial and ligamentary zones
- Peripheral nerve zones
- Local irritation or overload zone
Stage I — 0–6 weeks
INF-I locally, 2× per day, after acute irritation or overload. Evaluate at 6 weeks.
Stage II — 6 weeks – 3 months
INF-II locally, 2× per day, in the subacute phase after InflammaSacra I.
Stage III — >3 months
INF-III locally, 2× per day, in the chronic phase or with prolonged residual complaints.
On acute relapse: return to INF-I for the acute window, then re-enter the stage sequence. Confirm with EMG evaluation.
Chapter 06
Formulation science
The scientific philosophy of the composition: sequential formulation, phase relationship and ingredient rationale.
The composition read as an architecture, with the current formula held read-only and any proposed successor documented alongside it.
Documentation metadata+
Chapter 06 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Ingredient linksReservedEvery constituent resolving to its RM-001 entry.
- Version comparisonReservedSide-by-side comparison of current and proposed composition.
Composition
Formulation architecture
The composition is documented as a map rather than a list. Every constituent is recorded with the function it carries, the reason it is present in this field, how it relates to the rest of the composition and the cutaneous topical formulation category it belongs to.
- 01Aqua base
Aqua
Carrier system
- Functional role
- Carrier phase
- Formulation purpose
- Sets the water phase that determines spreadability across a defined surface field.
- Interaction within the composition
- Holds the humectant fraction in solution and carries the emulsified lipid phase evenly over the zone.
- 02Glycerin
Glycerin
Humectant
- Functional role
- Moisture binding
- Formulation purpose
- Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
- Interaction within the composition
- Balances the emollient fraction: the humectant governs the water phase, the emollient the lipid phase.
- 03Shea butter
Butyrospermum parkii butter
Emollient
- Functional role
- Skin-feel and occlusive body
- Formulation purpose
- Gives the texture enough body to stay on the applied zone rather than running along the hairline.
- Interaction within the composition
- Carries the lipid-soluble antioxidant fraction and slows the evaporation of the water phase.
- 04Panthenol
Panthenol
Conditioning agent
- Functional role
- Surface conditioning
- Formulation purpose
- Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
- Interaction within the composition
- Water-soluble; works alongside glycerin in the same phase without altering the emulsion.
- 05Tocopherol
Tocopherol
Antioxidant stabiliser
- Functional role
- Formulation stability
- Formulation purpose
- Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.
- Interaction within the composition
- Dissolved in the shea fraction; stabilises the constituents it is dispersed in rather than acting on the skin.
Reading the map
Constituents are grouped by formulation category: a carrier system that governs spread, a water phase that governs feel, a lipid phase that governs stay-time, and stabilising constituents that keep successive batches comparable. Interactions describe the composition only; no physiological effect is asserted.
Cutaneous topical formulation rationale
The formulation is built for reproducible application on the documented zones: a texture that spreads thinly, a controlled sensory profile and a composition suitable for repeated professional use.
Representative composition overview. The full INCI listing is published in the composition index.
Chapter 07
QR patient information
The label surface, generated from the digital record: what the formulation is, its timeline, application areas, safety and quality assurance.
The label surface of the record, generated from the digital record so patient information can never drift from the documentation.
Documentation metadata+
Chapter 07 — related anatomy
Related documents
Future references
- Printed QRReservedProduction-ready QR code bound to the published version.
Documentation
Downloads
Label
QR resources
Each package carries a QR code that resolves to this documentation record in the reader's language, together with the composition index and the current application protocol. Codes are versioned, so updated documentation reaches practitioners without relabelling.
Resolves to /products/inflammasacra
QR information
- Current QR resolves to
- /products/inflammasacra
- Current version
- 1.0
- Last update
- 2025-08
- Batch number
- INF-2508
Storage information
Store closed, upright and away from direct sunlight. Storage conditions are documented on the label and repeated here without alteration.
Professional information
Professional reading opens the complete monograph: anatomy, composition architecture, protocol and revision record.
Patient information
Essential reading describes what the composition is, where it is applied and in which order, without clinical interpretation.
- Multilingual QR contentReservedReserved: Dutch, English, French and German resolution of the same record.
Quality system
Version control
The current composition and any proposed successor are documented side by side. Approval and change control are handled outside the platform.
Current formula
- Version
- 1.0
- Revision date
- 2025-08
Initial approved composition.
Proposed formula
No successor is currently proposed for this record.
QR information
- QR target
- /products/inflammasacra
- Batch reference
- INF-2508
- Record status
- Documented
The QR code printed on the label resolves to this record. The product page is the single source of truth; printed material never carries content that is not documented here.
Controlled documents →Continue
Explore further
Cutaneous topical formulation. Information is provided for education and professional reference; it is not medical advice and implies no therapeutic effect.
Back to the ecosystem →